高级检索
当前位置: 首页 > 详情页

Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth

文献详情

资源类型:

收录情况: ◇ 自然指数

机构: [1]Third Mil Med Univ, Inst Pathol, Chongqing 400038, Peoples R China; [2]Third Mil Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing 400038, Peoples R China; [3]Minist Educ China, Key Lab Tumour Immunopathol, Chongqing 400038, Peoples R China; [4]Cleveland Clin, Lerner Res Inst, Dept Stem Cell Biol & Regenerat Med, Cleveland, OH 44195 USA; [5]Third Mil Med Univ, Southwest Hosp, Dept Ophthalmol, Chongqing 400038, Peoples R China; [6]Fourth Mil Med Univ, Xijing Hosp, Dept Neurol, Xian 710032, Peoples R China; [7]Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [8]Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing 400038, Peoples R China; [9]Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Guangzhou 510095, Guangdong, Peoples R China
出处:
ISSN:

摘要:
Intense infiltration of tumour-associated macrophages (TAMs) facilitates malignant growth of glioblastoma (GBM), but the underlying mechanisms remain undefined. Herein, we report that TAMs secrete abundant pleiotrophin (PTN) to stimulate glioma stem cells (GSCs) through its receptor PTPRZ1 thus promoting GBM malignant growth through PTN-PTPRZ1 paracrine signalling. PTN expression correlates with infiltration of CD11b(+)/CD163(+) TAMs and poor prognosis of GBM patients. Co-implantation of M2-like macrophages (MLCs) promoted GSC-driven tumour growth, but silencing PTN expression in MLCs mitigated their pro-tumorigenic activity. The PTN receptor PTPRZ1 is preferentially expressed in GSCs and also predicts GBM poor prognosis. Disrupting PTPRZ1 abrogated GSC maintenance and tumorigenic potential. Moreover, blocking the PTN-PTPRZ1 signalling by shRNA or anti-PTPRZ1 antibody potently suppressed GBM tumour growth and prolonged animal survival. Our study uncovered a critical molecular crosstalk between TAMs and GSCs through the PTN-PTPRZ1 paracrine signalling to support GBM malignant growth, indicating that targeting this signalling axis may have therapeutic potential.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 1 区 综合性期刊
小类 | 1 区 综合性期刊
最新[2023]版:
大类 | 1 区 综合性期刊
小类 | 1 区 综合性期刊
第一作者:
第一作者机构: [1]Third Mil Med Univ, Inst Pathol, Chongqing 400038, Peoples R China; [2]Third Mil Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing 400038, Peoples R China; [3]Minist Educ China, Key Lab Tumour Immunopathol, Chongqing 400038, Peoples R China;
通讯作者:
通讯机构: [1]Third Mil Med Univ, Inst Pathol, Chongqing 400038, Peoples R China; [2]Third Mil Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing 400038, Peoples R China; [3]Minist Educ China, Key Lab Tumour Immunopathol, Chongqing 400038, Peoples R China; [4]Cleveland Clin, Lerner Res Inst, Dept Stem Cell Biol & Regenerat Med, Cleveland, OH 44195 USA; [9]Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Guangzhou 510095, Guangdong, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43377 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号